A338840 Stock Overview
An antibody new drug development platform company, engages in the research and development of immuno-oncology drugs and antibody drugs.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Y-Biologics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩10,380.00 |
| 52 Week High | ₩23,800.00 |
| 52 Week Low | ₩7,570.00 |
| Beta | 0 |
| 11 Month Change | 12.83% |
| 3 Month Change | 8.01% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -18.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| A338840 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -11.6% | -4.2% | 2.4% |
| 1Y | n/a | 40.6% | 5.0% |
Return vs Industry: Insufficient data to determine how A338840 performed against the KR Biotechs industry.
Return vs Market: Insufficient data to determine how A338840 performed against the KR Market.
Price Volatility
| A338840 volatility | |
|---|---|
| A338840 Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in KR Market | 12.1% |
| 10% least volatile stocks in KR Market | 3.5% |
Stable Share Price: A338840 has not had significant price volatility in the past 3 months.
Volatility Over Time: A338840's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | Young Woo Park | www.ybiologics.com |
Y-Biologics, Inc., an antibody new drug development platform company, engages in the research and development of immuno-oncology drugs and antibody drugs. It develops YBL-006, a PD-1 immune checkpoint inhibitor that is in clinical phase 1/2a medication for solid cancers. The company also develops mono-specific antibodies, such as YBL-011 and YBL-003 for solid cancers; YBL-013, an ALiCE antibody for solid cancers; and YBL-001, an anti-drug conjugate for small cell lung and liver cancers.
Y-Biologics, Inc. Fundamentals Summary
| A338840 fundamental statistics | |
|---|---|
| Market cap | ₩153.31b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A338840 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A338840 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A338840 perform over the long term?
See historical performance and comparison